Skip to main content
OncoCyte seeks to raise $35M in public offering

A public offering of about 9.3 million shares of common stock has been priced by liquid biopsy test maker OncoCyte in hopes of raising about $35 million in gross proceeds. The money will be used to support the market launch of the company's blood-based assay, DetermaVu test, which is designed to differentiate between benign lung nodules and cancerous ones.

Full Story: